Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 2/20 | 0.30 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.30 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6762097 | 0.81 | ALOX15 (0.39) | ALOX15CYP3A4CA2 | |
| SCHEMBL6760712 | 0.79 | ELANE (0.35) | SLC15A1 | |
| SCHEMBL6760481 | 0.76 | CYP3A4 (0.36) | HPGDMEN1KMT2ACYP3A4TDP1 | |
| SCHEMBL6539682 | 0.72 | CHRM2 (0.39) | ALOX15MEN1KMT2ACYP3A4TDP1 | |
| SCHEMBL6760704 | 0.67 | CHRM3 (0.30) | — | |
| SCHEMBL2166654 | 0.67 | CHRM2 (0.61) | FAAHMGLL | |
| SCHEMBL2465566 | 0.66 | ALDH1A1 (0.58) | MEN1KMT2ATDP1L3MBTL1 | |
| SCHEMBL7755039 | 0.64 | CHRM2 (0.38) | ALOX15MEN1KMT2A | |
| SCHEMBL3772904 | 0.60 | ALOX15 (0.41) | ALOX15MEN1KMT2AFAAHMGLL | |
| SCHEMBL878243 | 0.59 | LMNA (0.45) | HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040186061-A1 | Novel derivatives of 3,3-diphenylpropylamines | SCHWARZ PHARMA AG | 2004-09-23 | — | — | US | disclosed |
| US-6713464-B1 | ANTIMUSCARINIC AGENTS WITH SUPERIOR PHARMACOKINETICS | SCHWARZ PHARMA AG (DE) | 2004-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186061-A1 | Novel derivatives of 3,3-diphenylpropylamines | ADRB3, ADRA1D, TNNC1 | HPGD 360/4885ALOX15 2393/4885MEN1 4504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.